Search Medical Condition
Please enter condition
Please choose location

Fano, Italy Clinical Trials

A listing of Fano, Italy clinical trials actively recruiting patients volunteers.

RESULTS

Found (44) clinical trials

ObservationaL Study on the Qol of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st Line

This is a national, multicentric, prospective, observational trial. The decision to prescribe FOLFOX or FOLFIRI plus panitumumab or FOLFOX or FOLFIRI plus cetuximab must have been freely taken by the clinician prior to the study entry for each patient included. Each physician will see his/her patients within the context of ...

Phase N/A

0.0 miles

Learn More »

Trastuzumab Optimization Trial in Breast Cancer

This project consists of two independent, following specific eligibility criteria and different randomisation schemes studies, later on called maintenance study and 2nd line study. All patients enrolled in the maintenance study, after disease progression should be screened to enter the 2nd line study. Maintenance study: Open-label, randomised, phase III, multicenter, ...

Phase

0.0 miles

Learn More »

Pemetrexed +/- Carboplatin as Second Line Treatment in NSCLC

In spite of the superiority of single agent over best supportive care in second-line NSCLC, the prognosis of these patients remains poor with a median survival of 6-7 months, justifying the evaluation of new regimens in this setting. An open question in the second-line treatment of NSCLC remains the possible ...

Phase

0.0 miles

Learn More »

CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer

Breast cancer is the most common form of cancer among women in North America, Europe and Latin America. Because nearly 80% of breast cancers are endocrine-responsive tumors, the majority of patients candidates for adjuvant chemotherapy (CT) are also candidates for endocrine therapy (ET). The optimal timing (i.e. concomitant vs sequential ...

Phase

0.0 miles

Learn More »

Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC

The purpose of this Phase IIIb study is to collect additional safety and efficacy data for the combination of ribociclib + letrozole in men and pre/postmenopausal women with HR+HER2- advanced breast cancer.

Phase

0.0 miles

Learn More »

Italian ClinicalService Project

ClinicalService is a project aiming to provide information and analysis of clinical and device data, back to the treating healthcare providers regarding their own patients, in order to help those healthcare providers improve outcomes and understanding of their patients' care or patients' management. The mission of the Italian ClinicalService Project ...

Phase N/A

0.0 miles

Learn More »

Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer

The co-primary objectives are to assess investigator-assess, and blinded independent centrally-reviewed progression-free survival .

Phase

0.0 miles

Learn More »

A Stepped Wedge Cluster Randomized Controlled Trial to Assess a Strategy Aiming to Optimize Psychosocial Outcomes in Patients With Cancer

INTRODUCTION Our group previously demonstrated the feasibility of the Hucare Quality Improvement Strategy - HQIS, aimed at integrating into practice 6 psychosocial interventions recommended by international guidelines. This randomized trial is designed to assess whether the introduction of the strategy in oncology wards improves patient quality of life. METHODS AND ...

Phase N/A

0.0 miles

Learn More »

Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CML) to Characterize the Efficacy and Safety of a Range of Doses

This is a multi-center, randomized, phase 2 trial to characterize the safety and efficacy of ponatinib over a range of 3 starting doses. Eligible participants must have chronic phase chronic myeloid leukemia (CP-CML) and have demonstrated resistance to treatment or have the T315I mutation.

Phase

7.21 miles

Learn More »

"InDACtion" vs "3+7" Induction in AML

The overall survival (OS) of older AML patients has not been improved during the last decades with intensive chemotherapy based on cytarabine combined with an anthracycline ("3+7"). Next generation sequencing technology reveals that mutations in genes involved in epigenetics are frequently mutated in AML (e.g. DNMT3a), suggesting an important role ...

Phase

7.21 miles

Learn More »